Common Contracts
2 similar null contracts by Celgene Corp /De/
CELGENE CORPORATION $500,000,000 2.875% SENIOR NOTES DUE 2021 $1,000,000,000 3.250% SENIOR NOTES DUE 2023 $1,500,000,000 3.900% SENIOR NOTES DUE 2028 $1,500,000,000 4.550% SENIOR NOTES DUE 2048Celgene Corp /De/ • February 9th, 2018 • Pharmaceutical preparations • New York
Pursuant to an Agreement and Plan of Merger, dated as of January 21, 2018, by and among the Company, Blue Magpie Corporation, a Delaware corporation and a wholly owned subsidiary of the Company (“Blue Magpie”) and Juno Therapeutics, Inc., a Delaware corporation (“Juno”), and subject to the conditions contained therein, Juno will merge with and into Blue Magpie, with Juno continuing as the surviving entity and as a wholly owned subsidiary of the Company.
CELGENE CORPORATION $500,000,000 2.450% SENIOR NOTES DUE 2015 $500,000,000 3.950% SENIOR NOTES DUE 2020 $250,000,000 5.700% SENIOR NOTES DUE 2040 UNDERWRITING AGREEMENT October 4, 2010Celgene Corp /De/ • October 5th, 2010 • Pharmaceutical preparations • New York
